Combination therapy using interleukin-2 and tumor necrosis facto

Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 2, 514 8, 424 852, A61K 3702, A61K 4505

Patent

active

050987020

ABSTRACT:
Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.

REFERENCES:
patent: 4863727 (1989-09-01), Zimmerman et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Combination therapy using interleukin-2 and tumor necrosis facto does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy using interleukin-2 and tumor necrosis facto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using interleukin-2 and tumor necrosis facto will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2008813

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.